With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Founded in 1992, Sirna Therapeutics was one of the earliest biotechnology companies focused on developing therapeutics based on RNA interference (RNAi), specifically using small interfering RNA (siRNA ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...

(MENAFN- EIN Presswire) EINPresswire/ -- The RNA interference (RNAi) technology market has been experiencing remarkable growth recently, driven by advances in genetic research and increasing interest ...

RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was generally well tolerated among 14 patients with kidney disease. The “select” ...

Please provide your email address to receive an email when new articles are posted on . RNA therapeutics lowered all-cause mortality, increased 6-minute walk distance and improved quality of life. RNA ...

(RTTNews) - Wave Life Sciences (WVE), a clinical-stage biotechnology company, on Thursday initiated the Phase 1 INLIGHT clinical trial for WVE-007, a novel, long-acting RNA-based therapeutic aimed at ...